Although the classic tumorigenesis pathway focusing on APC/KRAS/TP53 mutations has been established well in CRC 39, 40, the diverse biochemical properties of KRAS mutational isoforms to hydrolyze GTP and activate downstream signaling pathways still challenge scientists and physicians dramatically 41, 42. The gene discussed is KRAS; the disease is colorectal carcinoma.